Back to results
US 2026/0083726 A1Published application
Compositions, systems, and methods for treating cancer using tumor treating fields, chemotherapeutic agents, and anti-fibrotic agents
AssigneeNovocure GmbH
InventorsGitit LAVY-SHAHAF, Tali Voloshin-Sela, Lilach Avigdor
Life of this patent
Estimating the term…
Abstract
Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one chemotherapeutic agent and at least one anti-fibrotic agent.
Claims20
A method of reducing viability of cancer cells, the method comprising the steps of:
- (1) applying an alternating electric field to the cancer cells for a period of time;
- (2) administering at least one first composition to the cancer cells, wherein the at least one first composition comprises at least one chemotherapeutic agent, wherein the at least one chemotherapeutic agent is not sorafenib, sunitinib, imatinib, or a tyrosine kinase inhibitor;
- and
- (3) administering at least one second composition to the cancer cells, wherein the at least one second composition comprises at least one anti-fibrotic agent.
1 more element
A method of treating cancer in a subject, the method comprising the steps of:
- (1) applying an alternating electric field to a target region of the subject for a period of time;
- (2) administering at least one first composition to the subject, wherein the at least one first composition comprises at least one chemotherapeutic agent, wherein the at least one chemotherapeutic agent is not sorafenib, sunitinib, imatinib, or a tyrosine kinase inhibitor;
- and
- (3) administering at least one second composition to the subject, wherein the at least one second composition comprises at least one anti-fibrotic agent.
1 more element
A method, comprising the steps of:
- (1) applying an alternating electric field to a target region of the subject for a period of time;
- (2) administering at least one first composition to the subject, wherein the at least one first composition comprises at least one chemotherapeutic agent, wherein the at least one chemotherapeutic agent is not sorafenib, sunitinib, imatinib, or a tyrosine kinase inhibitor;
- and
- (3) administering at least one second composition to the subject,
- wherein the at least one second composition comprises at least one anti-fibrotic agent;
- and
- wherein administration of the alternating electric field increases the toxicity of the at least one first composition against cancer cells in the subject when compared to the administration of the at least one first composition to the subject in the absence of alternating electric field application.
4 more elements
Dependencies are inferred from the claim text.